跳到正文
原文
Medical Xpress·· 2026-10-21精选AI 评分85

miv-cel CAR T细胞疗法II期临床试验显示硬皮人综合征患者一年后行走能力显著提升

CAR T-cell therapy shows lasting improvements in stiff person syndrome, study finds

AI 导读

miv-cel CAR T细胞疗法在II期临床试验中显示硬皮人综合征患者一年后行走能力显著提升(患者行走时间中位数减少51%,67%不再需要辅助行走)。该研究由美国科罗拉多大学安舒兹医学院主导,计划于2026年第四季度提交FDA生物制剂许可申请,可能成为首个获批的针对硬皮人综合征的CAR T疗法。

推荐理由

原文明确给出II期临床试验结果及后续FDA审批计划,读者可据此了解CAR T细胞疗法在罕见病领域的潜在进展。

正文 · 原文
CAR T-cell therapy shows lasting improvements in stiff person syndrome, study finds
Credit: CU Anschutz Medical Campus

New research led by the University of Colorado Anschutz is offering hope to people living with stiff person syndrome (SPS), showing that a CAR T-cell therapy may help change the course of the disease, with patients experiencing significant improvements in mobility and overall disability that lasted at least one year after treatment.

SPS is a rare, progressive autoimmune neurological disease that causes debilitating muscle stiffness, painful spasms and difficulty walking. An estimated 80% of patients eventually require walking assistance or a wheelchair, and many face a risk of permanent disability.

The Phase 2 clinical trial, sponsored by Kyverna Therapeutics and led by principal investigator Amanda Piquet, M.D., director of the autoimmune neurology program at the CU Anschutz School of Medicine, evaluated an experimental CAR T-cell therapy called mivocabtagene autoleucel (miv-cel). The one-year findings were presented today at MSToronto26, an international conference focused on advances in multiple sclerosis and related neurological conditions.

Piquet shared that one year after receiving a single treatment of the experimental therapy, patients with SPS demonstrated significant improvements in mobility, completing a 25-foot walking test in nearly half the time it took before treatment. Also, two-thirds of patients who initially needed walking aids were able to complete a walking test without assistance. Beyond walking improvements, patients also experienced lasting reductions in muscle stiffness, sensitivity to stimuli and overall disability.

CAR T-cell therapy shows lasting improvements in stiff person syndrome, study finds
Piquet walking with a patient from the clinical trial. Credit: CU Anschutz Medical Campus

"What makes these findings so exciting is that we're seeing patients regain independence and do things they previously couldn't do without assistance. For a progressive disease with no approved therapies, these findings represent a major step forward," said Piquet, who is also the Céline Dion Foundation Endowed Chair in Autoimmune Neurology at CU Anschutz.

The treatment uses a patient's own immune cells, which are modified to target cells involved in the disease. Unlike conventional treatments that often require ongoing medication to manage symptoms and suppress immune activity, this approach aims to address the underlying autoimmune processes driving SPS, potentially offering longer-lasting benefits after a single treatment.

Key findings at one year

All 26 patients treated in the clinical trial completed the one-year study, allowing researchers to evaluate whether the improvements seen in the first several months continued over time.

  • Significant improvements in walking ability: One year after a single treatment, patients completed a 25-foot walking test in a median of 49% less time than before treatment.
  • Reduced need for walking aids: Of the 12 patients who initially required a walking aid to complete the walking test, eight (67%) no longer needed assistance during the test at one year.
  • Walking times comparable to healthy adults: More than one-third of patients (35%) completed the 25-foot walking test in under five seconds, a time comparable to that of typical healthy adults.
  • Less dependence on ongoing immunotherapy: At one year, 24 of 26 patients (92%) remained free of treatments that suppress or modify the immune system to manage SPS.
  • Benefits continued even as immune cells returned: In 65% of patients, the immune cells targeted by the treatment had begun returning by one year, yet clinical improvements were maintained. This suggests the therapy may have longer-lasting effects on the underlying autoimmune disease rather than simply providing temporary symptom relief.

Potential FDA approval

The findings from this registrational clinical trial are helping advance miv-cel toward potential FDA approval. Kyverna, the biopharmaceutical company that developed the CAR T-cell therapy, has stated its intention to complete its rolling biologics license application (BLA) submission in the fourth quarter of 2026.

If approved, miv-cel could become the first FDA-approved treatment specifically for stiff person syndrome and the first CAR T-cell therapy approved for an autoimmune disease.

"CAR T-cell therapy has the potential to change how we treat autoimmune diseases, offering lasting improvements without the need for ongoing immunotherapy," Piquet said. "We're hopeful this could lead to the first FDA-approved treatment for stiff person syndrome and open the door to an entirely new approach to treating autoimmune diseases."

Key medical concepts

Muscle Stiffness

Who's behind this story?

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: CAR T-cell therapy shows lasting improvements in stiff person syndrome, study finds (2026, October 21) retrieved 21 October 2026 from https://medicalxpress.com/news/2026-10-car-cell-therapy-stiff-person.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com